Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care

Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care

The treatment paradigm for metastatic castrate-sensitive prostate cancer (mCSPC) has evolved rapidly in the past decade with the approval of several life-prolonging therapies including docetaxel chemotherapy and multiple androgen receptor pathway inhibitors (ARPI) in combination with androgen depriv...

Full description

Bibliographic Details
Main Authors: Abhenil Mittal, Srikala S. Sridhar, Michael Ong, Di Maria Jiang
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Current Oncology
Subjects:
metastatic castrate sensitive prostate cancer
triplet therapy
androgen receptor pathway inhibitors
docetaxel
abiraterone
darolutamide
Online Access:https://www.mdpi.com/1718-7729/30/4/332

Internet

https://www.mdpi.com/1718-7729/30/4/332

Similar Items